|
Oxford Nanopore Technologies PLC on Monday left its full-year outlook unchanged, though revenue was higher-than-expected in the first half of 2025. The Oxford,England-based biomedical company focuses on DNA and RNA sequencing technology. It is expecting to report around £105 million in revenue for the six months that ended June 30, up by a quarter from £84.1 million a year prior. This 25% rise is ahead of the company’s expectations, it said. Trading was strongest for Oxford Nanopore’s PromethION product range, which boosted sales by about 59% on-year. Research and Applied Markets grew by 22% and 33% respectively, according to the firm. Revenue by region showed the strongest performance in Europe, the Middle East, Africa, India & Asia-Pacific, with 33% revenue growth at a constant currency rate. Despite an uncertain US research environment, Oxford Nanopore said revenue in the Americas grew by 17% at constant currency. Loss before interest, tax, depreciation and amortisation is estimated to have narrowed from a year prior, when Oxford Nanopore posted an Ebitda loss of £61.6 million. Ebitda loss for the first half of 2025 also narrowed from the second half of 2024, the firm said, when it had a £54.5 million loss. Back in March, Oxford Nanopore said it expects adjusted Ebitda to be break even in 2027 and for the company to become cash flow positive in 2028. Back in April, analysts at Peel Hunt said they were waiting to see the benefits of Oxford Nanopore’s contract wins. The broker noted exposure to budget cuts by the US National Institutes of Health, commenting: ‘We remain unsure that revenue growth is coming fast enough.’ Peel Hunt said the break-even point could be pushed back as late as 2032. Oxford Nanopore on Monday added that it expects a non-cash one-off cost related to inventory and currency headwinds for the first half of 2025, offsetting measures to improve the gross margin, now expected marginally below the previous year. In 2024, gross margin was 58.8%. Cash, cash equivalents and other liquid investments totalled about £337 million at June 30, down from £403.8 million a year before. Oxford Nanopore maintained that it is ‘well-capitalised’ and that a new pricing model, along with increased capex purchases by customers, is improving cash flow conversion. Oxford Nanopore shares were up 17% at 171.68 pence on Monday morning in London. The stock has risen 43% over the past 12 months. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
